taiba Make Strategic Investment in Immuneel Therapeutics to advance CAR T-cell Research and Make Therapies More Affordable

taiba has announced a strategic investment in Immuneel Therapeutics for $12 million.

This strategic investment is intended to advance CAR T-cell research, with a particular focus on making CAR-T cell therapy commercially available at affordable prices and developing the first Phase 2 trial for CD19 CAR-T (IMN-003A) targeting B-cell malignancies, including leukemia and lymphoma